Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
NAGIOS: RODERIC FUNCIONANDO

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

DSpace Repository

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

Show simple item record

dc.contributor.author Conget, Ignacio
dc.contributor.author Mauricio, Dídac
dc.contributor.author Ortega, Rafael
dc.contributor.author Detournay, Bruno
dc.contributor.author Muros, Teresa
dc.contributor.author De la Cuesta, Carmen
dc.contributor.author Mangas Cruz, Miguel Ángel
dc.contributor.author Hernández Herrero, Cristina
dc.contributor.author De Castro Hernández, Paloma
dc.contributor.author Gómez Peralta, Fernando
dc.contributor.author Miralles García, José Manuel
dc.contributor.author Martínez, Encarna
dc.contributor.author Cuatrecasas, Guillem
dc.contributor.author Aguilera, Eva
dc.contributor.author Giménez, Margarita
dc.contributor.author Vinagre, Irene
dc.contributor.author Anglada, Jordi
dc.contributor.author Pérez Maraver, Manuel
dc.contributor.author Manzanares, Jose María
dc.contributor.author Fernández Catalina, Pablo
dc.contributor.author Bellido Guerrero, Diego
dc.contributor.author Soto González, Alfonso
dc.contributor.author Casanueva, Felipe
dc.contributor.author Masmiquel, Lluís
dc.contributor.author Gómez, Luis Alberto
dc.contributor.author García, Honorato
dc.contributor.author Arguelles, Iñaqui
dc.contributor.author Garcia Puig, Juan
dc.contributor.author Brito Sanfiel, Miguel Ángel
dc.contributor.author Escalada, Francisco Javier
dc.contributor.author Gaztambide, Sonia
dc.contributor.author Hernández Mijares, Antonio
dc.contributor.author Ampudia Blasco, Francisco Javier
dc.contributor.author Tréscoli, Carlos
dc.contributor.author Merino Torres, Juan Francisco
dc.contributor.author De Teresa Parreño, Luis
dc.date.accessioned 2019-02-25T09:24:42Z
dc.date.available 2019-02-25T09:24:42Z
dc.date.issued 2016
dc.identifier.uri http://hdl.handle.net/10550/69173
dc.description.abstract Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design: Cross-sectional observational study. Setting: Spanish specialist outpatient clinics. Participants: 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures: Sociodemographic and DM2-related clinical data, including treatment at and after GLP-1Ra initiation and comorbidities, were collected. Results: Evaluable patients (n=403; 50.9% female) were included ( July 2013 to March 2014) at 24 centres by 53 specialists (47 endocrinology, 6 internal medicine), with the following profile (value±SD): age (58.3±10.4 years), diabetes duration (9.9±7 years), body mass index (BMI; 36.2±5.5) and glycated haemoglobin (HbA1c; 8.4±1.4%); 14% had HbA1c≤7%. Previous antidiabetic treatment: 53.8% only oral antidiabetic drugs (OADs), 5.2% insulin and 40% insulin and OAD; of those receiving OAD, 35% single drug, 38.2% 2 drugs and 24% 3 drugs. Concomitant to GLP-1Ra, 55.3% were only on OAD, 36.2% on insulin and OAD, and 7.2% only on insulin. Of those receiving OAD, the GLP-1Ra was mainly associated with 1 drug (65%) or 2 drugs (31.8%). GLP-1Ra are frequently added to existing antidiabetic drugs, with dipeptidyl peptidase-4 inhibitors being the OAD most frequently switched (45% receiving 1 before starting GLP-1Ra, only 2.7% receiving it concomitantly). Conclusions: In Spain, GLP-1Ra therapy is usually started in combination with OADs or OADs and insulin. These drugs are used in relatively young patients often not reaching therapeutic goals with other treatment combinations, roughly a decade after diagnosis and with a relatively high BMI. The latter could be explained
dc.language.iso eng
dc.relation.ispartof Bmj Open, 2016, vol. 6, p. e010197
dc.rights.uri info:eu-repo/semantics/openAccess
dc.source Conget, Ignacio Mauricio, Dídac Ortega, Rafael Detournay, Bruno Muros, Teresa De la Cuesta, Carmen Mangas Cruz, Miguel Ángel Hernández Herrero, Cristina De Castro Hernández, Paloma Gómez Peralta, Fernando Miralles García, José Manuel Martínez, Encarna Cuatrecasas, Guillem Aguilera, Eva Giménez, Margarita Vinagre, Irene Anglada, Jordi Pérez Maraver, Manuel Manzanares, Jose María Fernández Catalina, Pablo Bellido Guerrero, Diego Soto González, Alfonso Casanueva, Felipe Masmiquel, Lluís Gómez, Luis Alberto García, Honorato Arguelles, Iñaqui Garcia Puig, Juan Brito Sanfiel, Miguel Ángel Escalada, Francisco Javier Gaztambide, Sonia Hernández Mijares, Antonio Ampudia Blasco, Francisco Javier Tréscoli, Carlos Merino-Torres, Juan Francisco De Teresa Parreño, Luis 2016 Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain Bmj Open 6 e010197
dc.subject Malalties d'origen nutricional
dc.title Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
dc.type info:eu-repo/semantics/article
dc.date.updated 2019-02-25T09:24:42Z
dc.identifier.doi https://doi.org/10.1136/bmjopen-2015-010197
dc.identifier.idgrec 114002

View       (626.1Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics